Skip to main content
. 2015 Dec 22;10(Suppl 1):153–169. doi: 10.4137/BMI.S20054

Figure 5.

Figure 5

Patient and genome-modification paradigms for iPSCs. In the patient comparison paradigm (left, green box), genetically heterogenous iPSCs are compared in cohorts, revealing specific phenotypes (loss of PC2 and ciliary signaling defects in ADPKD patient). In the genome-modification paradigm (right, purple box), the original iPSCs are genetically modified (arrows) to introduce or correct genetic mutations and the corresponding phenotypes in isogenic lines.